Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06323018 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Effects of Remote Ischaemic Preconditioning in Cemented Hip Arthroplasty.

Study acronym: PRINCIPAL
StatusRecruiting
PhaseNot applicable
Started
View on ClinicalTrials.gov ↗
Record status
This record was last updated April 4, 2024 (before its estimated March 2026 completion). Its status may not reflect the trial's current state.

Record History

See every version on ClinicalTrials.gov ↗

  1. Secondary endpoints revised (10)v3
  2. Trial status: Not Yet Recruiting to Recruiting
    • Study sites: 0 to 1
    • Start date changed from estimate of Mar 2024 to Mar 20, 2024
    • Secondary endpoints revised (10)
    v2
  3. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Total joint arthroplasty is one of the best treatment options for end-stage osteoarthritis. Cemented hip arthroplasty is mainly indicated for elderly patients with poor bone quality and multiple comorbidities. Bone cement implantation syndrome is associated with cemented hip arthroplasty and it has been shown to increase cardiovascular and renal complication and brain damage postoperatively. The aim of this project is to elucidate whether remote-ischemic preconditioning (RIPC) has multi-organ protective effect in cemented hip arthroplasty patients.
Trial Details
NCT Number NCT06323018
Lead Sponsor University of Tartu
Conditions
(from sponsor)		 Osteoarthritis, Hip, Cardiovascular Diseases, Bone Cement Implantation Syndrome, Kidney Diseases
Related terms Cardiovascular Diseases, Kidney Diseases, Osteoarthritis, Hip
Enrollment 200 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov